Brief report: impact of consolidation durvalumab on unresectable non-small cell lung cancer with driver mutations

Unresectable stage III non-small cell lung cancer (NSCLC) carries a poor prognosis. The PACIFIC trial established consolidation durvalumab after chemoradiation as a standard treatment; however, its efficacy in patients with driver mutations remains uncertain. This retrospective cohort study analyzed...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Jason C.S. Ho, K.M. Cheung
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2024-01-01
Colecção:Cancer Treatment and Research Communications
Assuntos:
Non-small cell lung cancer
Chemoradiotherapy
Immunotherapy
Durvalumab
Real-world data
Acesso em linha:http://www.sciencedirect.com/science/article/pii/S2468294225000012
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados